Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1[Mepolizumab][1] Mepolizumab (Mepolizumab)[1] Mepolizumab (Mepolizumab) 💬 [1] IL5 💬 [13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬[2] 44, 45 💬
2Diagnostic Test: laboratory experiments before and after mepolizumab treatment[1] Mepolizumab (Mepolizumab)[1] Mepolizumab (Mepolizumab) 💬 [1] IL5 💬 [13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬[2] 44, 45 💬
3MEPOLIZUMAB[1] Mepolizumab (Mepolizumab)[1] Mepolizumab (Mepolizumab) 💬 [1] IL5 💬 [13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬[4] 44, 45, 98, 162 💬
4Mepolizumab (a-IL-5 antibody)[1] Mepolizumab (Mepolizumab)[1] Mepolizumab (Mepolizumab) 💬 [1] IL5 💬 [13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬[1] 162 💬
5Mepolizumab 100 mg[1] Mepolizumab (Mepolizumab)[1] Mepolizumab (Mepolizumab) 💬 [1] IL5 💬 [13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬[1] 98 💬
6Mepolizumab 100 MG Injection [Nucala][1] Mepolizumab (Mepolizumab)[1] Mepolizumab (Mepolizumab) 💬 [1] IL5 💬 [13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬[2] 44, 45 💬
7Mepolizumab 300 mg[1] Mepolizumab (Mepolizumab)[1] Mepolizumab (Mepolizumab) 💬 [1] IL5 💬 [13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬[3] 44, 45, 98 💬
8Mepolizumab Injection[1] Mepolizumab (Mepolizumab)[1] Mepolizumab (Mepolizumab) 💬 [1] IL5 💬 [13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬[1] 44 💬
9SB-240563 (mepolizumab)[1] Mepolizumab (Mepolizumab)[1] Mepolizumab (Mepolizumab) 💬 [1] IL5 💬 [13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬[2] 44, 45 💬